FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387305020> ?p ?o ?g. }

• W4387305020 abstract "Introduction: Prostate cancer is the second leading cause of cancer-related death among American men. Prostate tumor cells exhibit significant tropism for the bone and once metastasis occurs, survival rates fall significantly. Current treatment options are not curative and focus on symptom management. Immunotherapies are rapidly emerging as a possible therapeutic option for a variety of cancers including prostate cancer, however, variable patient response remains a concern. Chemotherapies, like cabozantinib, can have immune-priming effects which sensitize tumors to immunotherapies. Additionally, lower doses of chemotherapy can be used in this context which can reduce patient side effects. We hypothesized that a combination of chemotherapy (cabozantinib) and immunotherapy [Interleukin-27 (IL-27)] could be used to treat bone-metastatic prostate cancer and exert pro-osteogenic effects. IL-27 is a multi-functional cytokine, which promotes immune cell recruitment to tumors, while also promoting bone repair. Methods: To test this hypothesis, in vivo experiments were performed where syngeneic C57BL/6J mice were implanted intratibially with TRAMP-C2ras-Luc cells that are able to form tumors in bone. Immunotherapy was administered in the form of intramuscular gene therapy, delivering plasmid DNA encoding a reporter gene (Lucia), and/or a therapeutic gene (IL-27). Sonoporation was used to aid gene delivery. Following immunotherapy, the animals received either cabozantinib or a vehicle control by oral gavage. Bioluminescence imaging was used to monitor tumor size over time. Results: Combinatorial therapy inhibited tumor growth and improved survival. Further, RNA sequencing was used to investigate the mechanisms involved. Microcomputed tomography and differentiation assays indicated that the combination therapy improved bone quality by enhancing osteoblast differentiation and inhibiting osteoclast differentiation. Discussion: Our conclusion is that a chemo-immunotherapy approach such as the one examined in this work has potential to emerge as a novel therapeutic strategy for treating bone-metastatic prostate cancer. This approach will enable a significant reduction in chemotherapy-associated toxicity, enhance sensitivity to immunotherapy, and improve bone quality." @default.
• W4387305020 created "2023-10-04" @default.
• W4387305020 creator A5000129174 @default.
• W4387305020 creator A5005564582 @default.
• W4387305020 creator A5019247030 @default.
• W4387305020 date "2023-09-28" @default.
• W4387305020 modified "2023-10-18" @default.
• W4387305020 title "Cabozantinib and IL-27 combinatorial therapy for bone-metastatic prostate cancer" @default.
• W4387305020 cites W1145491420 @default.
• W4387305020 cites W1696978754 @default.
• W4387305020 cites W1831442001 @default.
• W4387305020 cites W1843886919 @default.
• W4387305020 cites W1903378835 @default.
• W4387305020 cites W1980046172 @default.
• W4387305020 cites W1980313076 @default.
• W4387305020 cites W2011139020 @default.
• W4387305020 cites W2013399798 @default.
• W4387305020 cites W2031928560 @default.
• W4387305020 cites W2034162675 @default.
• W4387305020 cites W2036897871 @default.
• W4387305020 cites W2047902191 @default.
• W4387305020 cites W2068408712 @default.
• W4387305020 cites W2079829796 @default.
• W4387305020 cites W2100945326 @default.
• W4387305020 cites W2102278945 @default.
• W4387305020 cites W2102979753 @default.
• W4387305020 cites W2104005232 @default.
• W4387305020 cites W2114104545 @default.
• W4387305020 cites W2117437691 @default.
• W4387305020 cites W2123077206 @default.
• W4387305020 cites W2134975411 @default.
• W4387305020 cites W2136566814 @default.
• W4387305020 cites W2140172658 @default.
• W4387305020 cites W2166182274 @default.
• W4387305020 cites W2166245676 @default.
• W4387305020 cites W2166662002 @default.
• W4387305020 cites W2179438025 @default.
• W4387305020 cites W2796134023 @default.
• W4387305020 cites W2801263515 @default.
• W4387305020 cites W2802903605 @default.
• W4387305020 cites W2884170377 @default.
• W4387305020 cites W2922886689 @default.
• W4387305020 cites W2928665623 @default.
• W4387305020 cites W2953757801 @default.
• W4387305020 cites W2991691094 @default.
• W4387305020 cites W2993803798 @default.
• W4387305020 cites W3014520066 @default.
• W4387305020 cites W3016919772 @default.
• W4387305020 cites W3027286012 @default.
• W4387305020 cites W3145969289 @default.
• W4387305020 cites W3207086895 @default.
• W4387305020 cites W3211402536 @default.
• W4387305020 doi "https://doi.org/10.3389/fmolb.2023.1259336" @default.
• W4387305020 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37842640" @default.
• W4387305020 hasPublicationYear "2023" @default.
• W4387305020 type Work @default.
• W4387305020 citedByCount "0" @default.
• W4387305020 crossrefType "journal-article" @default.
• W4387305020 hasAuthorship W4387305020A5000129174 @default.
• W4387305020 hasAuthorship W4387305020A5005564582 @default.
• W4387305020 hasAuthorship W4387305020A5019247030 @default.
• W4387305020 hasBestOaLocation W43873050201 @default.
• W4387305020 hasConcept C104317684 @default.
• W4387305020 hasConcept C111599444 @default.
• W4387305020 hasConcept C121608353 @default.
• W4387305020 hasConcept C126322002 @default.
• W4387305020 hasConcept C143998085 @default.
• W4387305020 hasConcept C151730666 @default.
• W4387305020 hasConcept C203014093 @default.
• W4387305020 hasConcept C2777701055 @default.
• W4387305020 hasConcept C2779013556 @default.
• W4387305020 hasConcept C2779343474 @default.
• W4387305020 hasConcept C2780007613 @default.
• W4387305020 hasConcept C2780192828 @default.
• W4387305020 hasConcept C2781064419 @default.
• W4387305020 hasConcept C502942594 @default.
• W4387305020 hasConcept C55493867 @default.
• W4387305020 hasConcept C71924100 @default.
• W4387305020 hasConcept C86803240 @default.
• W4387305020 hasConcept C8891405 @default.
• W4387305020 hasConceptScore W4387305020C104317684 @default.
• W4387305020 hasConceptScore W4387305020C111599444 @default.
• W4387305020 hasConceptScore W4387305020C121608353 @default.
• W4387305020 hasConceptScore W4387305020C126322002 @default.
• W4387305020 hasConceptScore W4387305020C143998085 @default.
• W4387305020 hasConceptScore W4387305020C151730666 @default.
• W4387305020 hasConceptScore W4387305020C203014093 @default.
• W4387305020 hasConceptScore W4387305020C2777701055 @default.
• W4387305020 hasConceptScore W4387305020C2779013556 @default.
• W4387305020 hasConceptScore W4387305020C2779343474 @default.
• W4387305020 hasConceptScore W4387305020C2780007613 @default.
• W4387305020 hasConceptScore W4387305020C2780192828 @default.
• W4387305020 hasConceptScore W4387305020C2781064419 @default.
• W4387305020 hasConceptScore W4387305020C502942594 @default.
• W4387305020 hasConceptScore W4387305020C55493867 @default.
• W4387305020 hasConceptScore W4387305020C71924100 @default.
• W4387305020 hasConceptScore W4387305020C86803240 @default.
• W4387305020 hasConceptScore W4387305020C8891405 @default.
• W4387305020 hasLocation W43873050201 @default.
• W4387305020 hasLocation W43873050202 @default.

• next